Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates by Curkovic, Ivanka et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Risks of inflammatory bowel disease treatment with glucocorticosteroids and
aminosalicylates
Curkovic, Ivanka; Egbring, Marco; Kullak-Ublick, Gerd A
Abstract: BACKGROUND: Glucocorticosteroids and aminosalicylates, mainly mesalazine (5-ASA), are
both standard therapeutics in the treatment of inflammatory bowel disease (IBD) patients. The gluco-
corticosteroids are highly effective in inducing remission in both ulcerative colitis and Crohn’s disease,
but their use is limited by the high incidence and the potentially serious nature of adverse events. In an
attempt to limit systemic side effects, rapidly metabolized corticosteroids such as budesonide have been
introduced. The safety profile of aminosalicylates differs between the formulations. METHODS: We
summarize the potential risks associated with glucocorticosteroid and aminosalicylate therapy in IBDs.
RESULTS: The numerous adverse events of glucocorticosteroids, particularly at high doses and prolonged
treatment, include opportunistic infections, diabetes mellitus, hypertension, ocular effects (glaucoma and
cataracts), psychiatric complications, hypothalamic-pituitary-adrenal axis suppression and increased frac-
ture risk. Partially, these systemic adverse events occur with budesonide, which only has a low systemic
exposure. The safety profile of 5-ASA is comparable to placebo and superior to the old aminosalicylate
prodrug sulfasalazine, which had a significantly higher incidence of intolerance reactions including allergic
rashes. Only in rare cases has nephrotoxicity such as interstitial nephritis been associated with 5-ASA.
CONCLUSION: Considering the toxicity profile of conventional glucocorticosteroids, one primary goal
of treatment in IBD should be corticosteroid-free remission. Therapy with budesonide may result in a
better safety profile. 5-ASA treatment is usually well tolerated, but with regard to the rare nephrotoxic
events, it is advisable to assess renal function before and during treatment with 5-ASA.
DOI: 10.1159/000354699
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-93477
Published Version
Originally published at:
Curkovic, Ivanka; Egbring, Marco; Kullak-Ublick, Gerd A (2013). Risks of inflammatory bowel disease
treatment with glucocorticosteroids and aminosalicylates. Digestive Diseases, 31(3-4):368-373. DOI:
10.1159/000354699
E-Mail karger@karger.com
 Adverse Events 
 Dig Dis 2013;31:368–373 
 DOI: 10.1159/000354699 
 Risks of Inflammatory Bowel Disease 
Treatment with Glucocorticosteroids and 
Aminosalicylates 
 Ivanka Curkovic    Marco Egbring    Gerd A. Kullak-Ublick  
 Department of Clinical Pharmacology and Toxicology, University Hospital Zürich,  Zürich , Switzerland
 
ic exposure. The safety profile of 5-ASA is comparable to pla-
cebo and superior to the old aminosalicylate prodrug sul-
fasalazine, which had a significantly higher incidence of in-
tolerance reactions including allergic rashes. Only in rare 
cases has nephrotoxicity such as interstitial nephritis been 
associated with 5-ASA.  Conclusion:  Considering the toxicity 
profile of conventional glucocorticosteroids, one primary 
goal of treatment in IBD should be corticosteroid-free remis-
sion. Therapy with budesonide may result in a better safety 
profile. 5-ASA treatment is usually well tolerated, but with 
regard to the rare nephrotoxic events, it is advisable to assess 
renal function before and during treatment with 5-ASA. 
 © 2013 S. Karger AG, Basel 
 Glucocorticosteroids 
 Introduction 
 Systemic glucocorticoids are effective at inducing re-
mission in both ulcerative colitis (UC) and Crohn’s dis-
ease (CD)  [1–4] , whereas they are ineffective in the main-
tenance of remission in either illness  [5] . However, their 
use is limited by their frequent, various and sometimes 
serious side effects: the most frequent and most typical 
side effects concern the skin, such as thinning of the skin 
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 Abstract 
 Background: Glucocorticosteroids and aminosalicylates, 
mainly mesalazine (5-ASA), are both standard therapeutics 
in the treatment of inflammatory bowel disease (IBD) pa-
tients. The glucocorticosteroids are highly effective in induc-
ing remission in both ulcerative colitis and Crohn’s disease, 
but their use is limited by the high incidence and the poten-
tially serious nature of adverse events. In an attempt to limit 
systemic side effects, rapidly metabolized corticosteroids 
such as budesonide have been introduced. The safety profile 
of aminosalicylates differs between the formulations.  Meth-
ods:  We summarize the potential  risks associated with glu-
cocorticosteroid and aminosalicylate therapy in IBDs.  Re-
sults: The numerous adverse events of glucocorticosteroids, 
particularly at high doses and prolonged treatment, include 
opportunistic infections, diabetes mellitus, hypertension, 
ocular effects (glaucoma and cataracts), psychiatric compli-
cations, hypothalamic-pituitary-adrenal axis suppression 
and increased fracture risk. Partially, these systemic adverse 
events occur with budesonide, which only has a low system-
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or purpura. Steroids affect bone and can induce both os-
teonecrosis and osteoporosis  [6] . They increase suscepti-
bility to various fungal, viral and bacterial infections  [7] . 
Myopathy is an infrequent complication, typically pre-
senting as proximal weakness of both the upper and low-
er extremities and sometimes with atrophy and paresis 
 [8] . Furthermore, steroids predispose to a range of psy-
chiatric complications such as depression, insomnia or 
euphoria  [9] . Cushingoid features with weight gain and 
redistribution of body fat are often quite troubling to the 
patients. Besides, a relevant proportion of patients devel-
op hyperglycemia. Especially if glucocorticosteroids are 
used in combination with nonsteroidal anti-inflammato-
ry drugs, the risk for peptic ulcer disease is significantly 
increased. The impact of glucocorticosteroids on athero-
sclerotic disease is supposed to be partly mediated by 
changes in lipoprotein levels  [10] . Ophthalmologic ad-
verse effects include both glaucoma and cataract (poste-
rior subcapsular cataracts are typical). Finally, if systemic 
glucocorticoids are stopped without adequate tapering, 
adrenal insufficiency may develop.
 In order to limit systemic toxicity, novel steroids with 
limited oral bioavailability such as the second-generation 
glucocorticosteroid budesonide have been developed as 
an alternative to classic corticosteroids. Budesonide ex-
erts its local effects due to its high affinity to the glucocor-
ticoid receptor, which is approximately 200 times that of 
prednisolone  [11] . Budesonide has a limited systemic 
bioavailability of only 10–15% due to extensive first-pass 
metabolism by cytochrome P-450 enzymes. But, potent 
CYP3A4 inhibitors such as macrolide antibiotics (cla-
rithromycin, erythromycin) or azole antifungals (keto-
conazole, itraconazole) can increase plasma concentra-
tions to a relevant extent  [12, 13] and consequently may 
increase the risk for systemic budesonide-associated side 
effects.
 Budesonide and Systemic Adverse Events 
 Despite its low oral bioavailability, adverse events
were more common in CD patients treated with 6 mg 
budesonide daily for maintenance of remission than with 
placebo according to a recent Cochrane analysis (RR 1.49; 
95% CI 1.01–2.19)  [14] , but adverse events were usually 
mild and did not result in increased rates of study with-
drawal. On the contrary, compared with conventional 
corticosteroids used for the induction of remission in CD, 
patients who received budesonide had significantly less 
systemic side effects (RR 0.64; 95% CI 0.54–0.76)  [15] . 
Abnormal responses to ACTH tests were significantly 
more common in budesonide-treated patients (both 3 
and 6 mg) than in those who received placebo (RR 2.73; 
95% CI 1.34–5.57 and RR 2.88; 95% CI 1.72–4.82)  [15] 
but less common than in patients who received conven-
tional glucocorticosteroids for the induction of remission 
in CD (RR 0.65; 95% CI 0.55–0.78)  [15] .
 Glucocorticosteroids and Hyperglycemia 
 Glucocorticosteroids are the most common cause of 
drug-induced diabetes mellitus. More than 50% of pa-
tients who receive glucocorticosteroids at a dose equiva-
lent of 40 mg prednisolone or more per day develop hy-
perglycemia  [16, 17] . The odds ratio for the development 
of a new-onset diabetes mellitus is 1.36–2.31  [18] . Predis-
posing factors are a family history of diabetes, a hospital-
ization in the preceding 4 months, a preexisting glucose 
intolerance, obesity, higher age and most importantly 
dose and duration of glucocorticoid therapy. Glucocor-
ticosteroids induce hyperglycemia mainly through in-
creased insulin resistance. Typically, postprandial glu-
cose is elevated while fasting glucose concentrations are 
often normal if glucocorticosteroids are administered 
once daily. It is recommended to monitor random plasma 
glucose, typically in the afternoon or 1–2 h postprandi-
ally. There are currently no published guidelines for the 
monitoring of plasma glucose in patients with inflamma-
tory bowel disease (IBD) with glucocorticosteroid thera-
py, but at least at the start of therapy, it may be advisable 
to check glucose not less than once weekly in patients who 
receive high doses of corticosteroids and who have no or 
only few risk factors for the development of steroid-in-
duced diabetes. In patients with several risk factors, glu-
cose concentrations should be tested at least once weekly. 
To treat hyperglycemia, oral antidiabetics such as metfor-
min or sulfonylureas may be used if glucose concentra-
tions are <12–15 mmol/l. If concentrations are higher, 
insulin therapy should be started. Longer-acting NPH in-
sulin has a similar action profile to prednisone and pred-
nisolone and can be given once daily in the morning. 
Therefore, NPH insulin can serve as a simple alternative 
for prandial insulin therapy.
 Hypothalamus-Pituitary-Adrenal Axis 
 Already 5 days of treatment with higher doses of glu-
cocorticoids (>25 mg/day prednisone or equivalent) in-
duce at least a partial suppression of the hypothalamus-
pituitary-adrenal (HPA) axis in 40% of patients  [19] . 
Whether this is clinically relevant is dependent on the in-
dividual stress level of the patient, such as trauma, acute 
infection or critical illness. In order to avoid both cortisol 
deficiency and acute flare-up of disease, careful tapering 
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of the glucocorticoid dose is mandatory. To date, there is 
no published ‘gold standard’ for tapering of glucocortico-
steroids in IBD patients and several possible regimes ex-
ist. One approach is to decrease prednisone/prednisolone 
dose by 5 mg weekly until a daily dose of 20 mg is achieved. 
Below 20 mg, the dose is tapered by 2.5 mg (to 5 mg) 
weekly, until therapy is stopped. HPA axis function test-
ing is ideal 1 day after finishing steroid therapy, but, in 
exceptional cases (e.g. if the dose cannot be reduced any 
further), it may be performed at prednisone doses  ≤ 5 mg. 
A simple test for measuring HPA function is the ACTH 
stimulation test. Two types exist, the ‘classical’ (Synac-
then ® ) test with 250 μg corticotropin given intravenous-
ly and the low-dose test with 1 μg corticotropin given in-
travenously. Several studies have concluded that the low-
dose test is slightly more sensitive than the classical test 
for detecting secondary adrenal insufficiency  [20–22] . 
The stimulated cortisol level is considered normal >500 
nmol/l (18 mg/dl). 
 Infection Risk 
 Glucocorticosteroid therapy predisposes to infections 
and several studies have evaluated the risk of infectious 
complications in IBD patients treated with corticoste-
roids. According to a TREAT registry (Crohn’s Therapy 
Resource, Evaluation, and Assessment Tool registry) 
analysis that compared infliximab safety with nonbiolog-
ical drug therapy, prednisone therapy was independently 
associated with serious infections (HR 1.57; 95% CI 1.17–
2.10) and also with an increased mortality risk (HR 2.14; 
95% CI 1.55–2.95)  [23] . In a case-control study in 100 
IBD patients with opportunistic infections, glucocortico-
steroids alone yielded an OR of 2.2 (95% CI 1.0–4.9) after 
multivariate analysis, whereas infection risk further in-
creased with the number of immunosuppressives (OR 
14.5; 95% CI 4.9–43.0 for 2 or 3 drugs)  [24] . Glucocorti-
costeroid therapy in IBD patients undergoing elective 
bowel surgery significantly increased postoperative infec-
tion risk according to a retrospective cohort study (OR 
3.69, 95% CI 1.24–10.97 for any infectious complications) 
 [25] . According to another case-control study, glucocor-
ticosteroids were the only independent risk factor for in-
fections in infliximab-treated patients (OR 2.69; 95% CI 
1.18–6.12)  [26] .
 Effects on Bone 
 The prevalence of osteoporosis (with a T score <–2.5) 
in IBD patients is high, ranging from 18 to 42% in clinical 
studies, whereas the reported prevalence rates of osteope-
nia are even higher (22–77%)  [27–29] . The main factors 
contributing to the development of osteoporosis in IBD 
patients are disease activity and glucocorticosteroid use, 
but since these are closely linked, it is difficult to differen-
tiate between both factors in terms of impact on bone loss. 
Glucocorticosteroids increase bone resorption and bone 
remodeling rate early after starting therapy and also re-
duce bone formation. Factors contributing to glucocorti-
coid-induced bone loss are the suppression of osteoclast-
inhibiting factors such as osteoprotegerin and the induc-
tion of the formation of osteoclastogenic factors, such as 
receptor activator of nuclear factor-κB ligand  [30] . Bone 
loss and fracture risk increase rapidly (in the first 3–6 
months) after initiation of therapy and are dose-depen-
dent. Interestingly, an increase in fracture risk has already 
been demonstrated with doses as low as 2.5–7.5 mg pred-
nisone daily and not only with doses exceeding 7.5 mg 
daily  [31] . The greatest risk is seen for vertebral fractures 
 [31] . Upon cessation of glucocorticosteroid therapy,
fracture risk rapidly declines  [31] . Data evaluating oral 
budesonide effects on bone is sparse, but in one trial cor-
ticosteroid-naive CD patients treated with budesonide 
showed better preserved bone mineral density than those 
treated with prednisolone  [32] . Intervention thresholds 
for the management of glucocorticoid-induced bone loss 
vary among countries and among different societies, but 
in general, treatment should be considered in patients ex-
posed to systemic glucocorticosteroids  ≥ 3 months  [33–
35] . Bisphosphonates are still the treatment of choice.
 Aminosalicylates 
 Introduction 
 Aminosalicylates have been used in the treatment of 
IBDs for more than 60 years now. They are established 
therapies for inducing and maintaining remission in UC 
 [36, 37] , whereas their efficacy is not proven in the treat-
ment of CD  [5, 38] . A recent Cochrane review suggests 
that mesalazine (5-aminosalicylic acid, 5-ASA) is not ef-
fective in maintaining medically-induced remission in 
CD  [39] . Aminosalicylates chemically originate from sul-
fasalazine, which was initially developed for the treat-
ment of rheumatologic diseases in the 1940s. Sulfasala-
zine is split by bacterial azoreductase in the colon into the 
inactive sulfapyridine and the therapeutic mesalazine 
moiety. The discovery that 5-ASA is the active part of sul-
fasalazine was followed by the development of many dif-
ferent 5-ASA formulations (oral, rectal, pH-independent 
continuous release, pH-dependent release, multimatrix 
technology) allowing release in both the colon and/or 
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small intestine. Meanwhile, several aminosalicylates (sul-
fasalazine, olsalazine, balsalazide and mesalazine) are 
available for use in IBDs, but in the USA more than 88% 
of patients receive 5-ASA  [40, 41] . The mechanism of ac-
tion of 5-ASA in UC is complex and several effects have 
been observed  [42] . It is believed that 5-ASA interacts 
with damaged epithelium and mediates its effect locally 
on the mucosa. 5-ASA is a scavenger of reactive oxygen 
metabolites and inhibits leukocyte chemotaxis  [43] . Be-
sides, 5-ASA targets several intracellular pathways lead-
ing to changes in gene regulation: tumor necrosis factor-α/
nuclear factor-κB, transforming growth factor-β, inter-
leukin-1 and epidermal growth factor signaling, protein 
synthesis and Wnt/b-catenin signaling, peroxisome pro-
liferator-activated receptor-γ  and apoptosis  [44–46] .
 Adverse Events 
 Compared to 5-ASA, side effects occur more often 
with sulfasalazine therapy, with an adverse event rate 
ranging from 10 to 45%, depending on the sulfasalazine 
dose  [47–49] . Frequent adverse effects are headache, nau-
sea, epigastric pain or rash. Several adverse effects like 
hypersensitivity reactions were attributed to the inactive 
sulfapyridine moiety, which is absorbed from the colon. 
Slow acetylator genotype of N-acetyltransferase-2 may 
predispose to sulfasalazine-associated adverse effects 
 [50–52] . Some of the rare, but potentially serious adverse 
effects are blood dyscrasias like agranulocytosis  [53] , al-
veolitis  [54, 55] and pancreatitis  [56] . In contrast, 5-ASA 
therapy is well tolerated and the adverse event rate of 
5-ASA (e.g. gastrointestinal disturbances such as abdom-
inal pain, flatulence, nausea, dyspepsia) is 5%, which is 
similar to placebo according to several randomized con-
trolled clinical trials  [57, 58] . The incidence of intolerance 
reactions is significantly lower than with sulfasalazine 
therapy. Besides, according to a recent Cochrane review 
 [58] ,  high 5-ASA doses are not associated with a higher 
incidence of adverse effects and are as safe as low doses.
 Nephrotoxicity 
 Numerous cases of nephrotoxicity have been described 
for 5-ASA therapy  [59–64] . Nevertheless, several studies 
evaluating the effect of 5-ASA on renal function conclude 
that nephrotoxicity is a rare event: according to data from 
an adverse event monitoring in the United Kingdom,
interstitial nephritis was reported in 11.1 per 1 million 
5-ASA prescriptions  [65] . In a retrospective survey in pa-
tients with CD, long-term 5-ASA use led to a mean de-
cline in glomerular filtration rate of 0.3 ml/min/year 
which did not exceed the decline expected from physio-
logic aging  [66] . In a large epidemiologic study the inci-
dence rate of renal disease was higher in IBD patients 
without 5-ASA therapy (0.25/100 patients per year) com-
pared to those with 5-ASA use (0.17/100 patients per 
year)  [67] . According to an analysis from a postal ques-
tionnaire (United Kingdom) the incidence of nephrotox-
icity was estimated at 1/4,000 patients per year in 5-ASA 
users  [68] . 5-ASA-related nephrotoxicity typically pre-
sents as interstitial nephritis, which often occurs in the 
first 12 months of therapy  [69] , but can potentially occur 
at any time. If detected early, interstitial nephritis seems 
to be reversible  [63, 64] . Currently, there are no estab-
lished monitoring guidelines, but it may be advisable to 
check renal function before and every 3–6 months during 
aminosalicylate therapy.
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